10 results about "Bufadienolide" patented technology

The invention provides a content detection method for a salvia miltiorrhiza medicinal material, a salvia miltiorrhiza clear paste and a musk heart-dredging dropping pill. According to the method, a high performance liquid chromatography method is adopted, octadecylsilane chemically bonded silica is used as a chromatographic column filler, acetonitrile is used as a mobile phase A, 0.02%-0.1% trifluoroacetic acid is used as a mobile phase B, gradient elution is carried out, and rosmarinic acid and salvianolic acid B in the salvia miltiorrhiza medicinal material are synchronously and quantitatively detected. And synchronously and quantitatively detecting tanshinol, protocatechuic aldehyde, caffeic acid, salvianolic acid E, rosmarinic acid, alkannic acid and salvianolic acid B in the salvia miltiorrhiza clear paste, and synchronously and quantitatively detecting tanshinol, protocatechuic aldehyde, caffeic acid, salvianolic acid E, rosmarinic acid, alkannic acid, salvianolic acid B, arenobufagin and bufalin in the musk Tongxin dropping pill. The method is used for monitoring the content of specific components, can also judge the transfer rate in the medicine production process, and facilitates traceability in the production link. In addition, the method is relatively low in equipment requirement and suitable for industrial popularization.

The invention provides a monascus strain ZX-99 capable of expressing multiple beneficial active substances and application of the monascus strain ZX-99, and belongs to the technical field of microorganisms. The preservation number of the monascus strain ZX-99 provided by the invention is CGMCC No.40962, the strain does not produce citrinin (the detection limit is 25 mg / kg), and compared with other monascus cheese and commercially available mould cheese, the prepared cheese sample has the advantages that the content of citrinin in the cheese sample is greatly reduced, and the content of citrinin in the cheese sample is greatly reduced. Substances such as oxymatrine, bufalin, azadirachtin, gamma-aminobutyric acid, hydroxybenzylamine, maleic acid, maltotriose, maltotetraose and diacetyl are enriched in the monascus cheese ZX-99, and the monascus cheese ZX-99 is expected to be used for developing biological functional dairy products or compounding flavor strains.

The invention aims to catalyze bufalin and resibufogenin to modify and synthesize bufadienolide compounds, and discloses five newly discovered bufo bufo gargarizans source P450 enzymes, enzyme compositions, nucleic acids, expression vectors, bioengineering strains, methods and applications. The invention also discloses reported enzymes and enzyme compositions, nucleic acids, expression vectors, bioengineering strains, methods and applications of the P450 enzyme Sth10 related to catalysis of bufalin and resibufogenin for modification and synthesis of bufadienolide compounds. The amino acid sequence of the P450 enzyme is as shown in SEQ ID NO. 1-6. According to the invention, a plurality of P450 enzymes capable of modifying bufalin and / or resibufogenin at a fixed point under a mild condition are discovered for the first time, and a bioengineering strain and a biocatalytic synthesis method are developed based on the enzymes, so that a novel biosynthesis method for synthesizing bufadienolide compounds is established.

The invention provides application of resibufogenin in preparation of a medicine for resisting porcine epidemic diarrhea virus, and belongs to the technical field of chemical medicines. Experimental results show that resibufogenin has remarkable inhibiting and blocking effects on a-1 ribosomal Frameshift process of a porcine epidemic diarrhea virus (PEDV), can effectively inhibit replication and proliferation of the PEDV, and has an inhibiting effect on a plurality of common strains of the PEDV; the resibufogenin can be used for preparing a medicine for resisting PEDV and a medicine for preventing and treating porcine epidemic diarrhea caused by PEDV, and the medicine is a wide-spectrum antiviral medicine, is insensitive to variation of PEDV and has a wide application prospect.

The application discloses a nanometer preparation of bufonin for treating colon cancer, which has a core-shell structure, wherein the inner core is a nanocrystal composed of bufonin and a stabilizer, and the outer shell is a pH-responsive material and a pore-forming agent; the nanometer preparation of bufonin for treating colon cancer is prepared by using the stabilizer, the bufonin and the pH-responsive material; the in-vitro dissolution characteristics of the poorly soluble drug bufonin are improved by nanometerization treatment, and the dissolution characteristics are obviously improved compared with the raw drug; the pH responsiveness of the Eudragit L-100 protects the bufadienolides in the bufonin from being destroyed by the strong acidic condition of gastric juice, thereby improving the stability and effectiveness of the drug, reducing the initial release of bufalin, cinobufagin and resibufogenin in the stomach, making the drug target the intestinal site, making the three kinds of bufonin components achieve effective and rapid synergistic release in the intestinal site, increasing the utilization rate of the drug in the intestinal tract, and being beneficial to the treatment of colon cancer.

The application belongs to the technical field of medicine, and particularly relates to application of butaclamol in preparation of anti-influenza virus products. The application proves through in-vivo and in-vitro experiments that butaclamol can play an antiviral role by inhibiting replication of H1N1. The in-vitro antiviral effect of butaclamol is superior to that of positive drug oseltamivir, and intragastrically administered butaclamol can reduce the mortality of mice by reducing replication of H1N1 in vivo, and has good practical application value in development of anti-influenza virus drugs.

The invention discloses a P450 enzyme, an enzyme composition, nucleic acid, an expression vector, a bioengineering strain, a method and application. The amino acid sequence of the P450 enzyme is as shown in SEQ ID NO. 1. According to the invention, the P450 enzyme capable of modifying bufalin and / or resibufogenin at a fixed point under a mild condition is found for the first time, and a bioengineering strain and a biocatalytic synthesis method are developed based on the P450 enzyme, so that a biosynthesis method for efficiently synthesizing bufadienolide compounds is established.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a bufogenin compound derivative as well as a preparation method and application thereof. The bufogenin compound derivative provided by the invention has a structural formula as shown in a formula (I). The toad lactone compound is a series of structural compounds with 14-site hydroxyl and 15-site basic groups (containing N heterocyclic rings, aliphatic amine or aromatic amine) through ring opening by taking a toad lactone compound containing 14-site and 15-site epoxy rings as a raw material, and the IC50 inhibition concentration of the toad lactone compound to Huh-7, HN4 and HEP G2 is obviously lower than that of a toad lactone compound represented by bufalin. The compound has an excellent effect of inhibiting proliferation of liver cancer cells or laryngeal squamous cell carcinoma cells, and is expected to be developed into novel anti-liver cancer or anti-laryngeal squamous cell carcinoma drugs.

The application discloses a method for extracting bufadienolides in bufonis medicinals and application thereof, and belongs to the technical field of effective component extraction of traditional Chinese medicines. The method uses a deep eutectic solvent (DES) as an extracting agent, and solves the problems of low purity of bufadienolides, poor extraction efficiency and complicated process in traditional water extraction or alcohol extraction methods by optimizing the solvent composition, material ratio and extraction process. The method has high extraction efficiency, can significantly improve the total content of bufalin, resibufogenin and cinobufagin in the extract, and is simple in process, environment-friendly and easy for large-scale industrial production, thereby providing a new approach for efficient utilization of bufonis medicinals.

The invention discloses a method for extracting toad steroid total lactone in toad medicinal materials and application of the toad steroid total lactone, and belongs to the technical field of extraction of effective components of traditional Chinese medicines. According to the method, a deep eutectic solvent (DES) is taken as an extracting agent, and the problems of low purity, poor extraction efficiency and tedious process of toad sterol total lactone in a traditional water extraction or alcohol extraction method are solved by optimizing the solvent composition, the material ratio and the extraction process. The method is high in extraction efficiency, the total content of bufalin, resibufogenin and cinobufagin in the extract can be remarkably increased, the process is simple and environmentally friendly, large-scale industrial production is easy, and a new way is provided for efficient utilization of toad medicinal materials.